Sign inJoin waitlistJoin the waitlist

FM

Fataneh Majlessipour

Physician · Cedars-Sinai Medical Center

Credentials: · ·

History

Cedars-Sinai Medical Center
Present

Children Hospital Los Angeles Pediatric Hematology Oncology
1999–2000
Children's Hospital of Orange County
1994–1997
Isfahan University of Medical Sciences and Health Services Faculty of Medicine
1986–1990

Research

A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute…
Blood · 2002 · 380 citations
Primary EBV infection resulting in lymphoproliferative disease in a teenager with Crohn disease
Case report · Journal of Pediatric Gastroenterology and Nutrition · 2011 · 17 citations
Altered type 1 interferon responses in alloimmunized and nonalloimmunized patients with sickle cell disease
eJHaem · 2021 · 13 citations

NB
Nicole Baca
8 papers
Moise Danielpour
3 papers
Kenneth Weinberg
2 papers
AK
Alon Kashanian
1 paper
Ashley Wachsman
1 paper
Behrooz Hakimian
1 paper
BL
Beverly Lange
1 paper
Bonnie Balzer
1 paper
BB
Bruce Bostrom
1 paper
CL
Carol Lin
1 paper
CH
Chelsea Halprin
1 paper · 1 as a resident
Chelsea Hayes
1 paper

Clinical trials

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2029
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Site PI · Recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2022–2027
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Site PI · Recruiting · Phase 2
Children's Oncology Group
2021–2029
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Site PI · Recruiting · Phase 3
Children's Oncology Group
2020–2029